Kalium Chloratum Wzf (Potassium Chloride)

After infusion, potassium chloride dissociates into potassium and chloride ions. The added potassium raises extracellular potassium concentration, helping to restore normal membrane potential in nerve and muscle cells, which is critical for proper cardiac rhythm and muscle function.

The dose is individualized by the prescribing clinician based on the patient’s serum potassium level, underlying condition, renal function, and overall clinical status. Only a qualified healthcare professional should determine the appropriate infusion rate and total amount.

The pregnancy safety category is not established. Use during pregnancy or lactation only if the potential benefit justifies the potential risk and after careful evaluation by the treating physician.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Kalium Chloratum Wzf is an injectable formulation, allowing rapid correction of potassium deficits, whereas oral potassium salts (e.g., potassium gluconate tablets) provide slower, more gradual replenishment. Intravenous delivery is preferred in acute or severe hypokalemia, especially when oral intake is not feasible.

The solution should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the container tightly sealed and retain it in its original packaging until use.

It is given by slow intravenous infusion under medical supervision. The infusion rate is adjusted according to the patient’s serum potassium level and clinical condition, with continuous monitoring to avoid rapid shifts that could cause cardiac complications.

The most critical risks include severe hyperkalemia leading to life‑threatening cardiac arrhythmias, anaphylactic reactions, and infusion‑related complications such as thrombophlebitis. Prompt monitoring of serum potassium and cardiac status is essential during treatment.

Patients with existing hyperkalemia, severe renal failure, or those taking other potassium‑increasing agents (e.g., potassium‑sparing diuretics, ACE inhibitors) without appropriate monitoring should not receive this product unless a physician determines it is safe.